title: Additive effects of calcipotriol and cyclosporine A: from in vitro experiments to in vivo applications in the treatment of severe psoriasis.
abstract: We report that calcipotriol (CPT) is a potent inhibitor of lymphocyte proliferation in mixed epidermal cell lymphocyte reactions. In this model, CPT and cyclosporine A (CsA) have synergistic effects. These results have led to a randomised double-blind therapeutic study protocol in patients with severe psoriasis. In these patients, topical CPT and sub-therapeutic doses of CsA (2mg/kg/d) induce disappearance of cutaneous lesions. This therapeutic association may minimize secondary side effects of both drugs.
authors.affiliation: Service de Dermatologie, Hôpital Henri-Mondor, Créteil, France.
authors.forename: M
authors.initials: M
authors.lastname: Bagot
authors.forename: R
authors.initials: R
authors.lastname: Grossman
authors.forename: R
authors.initials: R
authors.lastname: Pamphile
authors.forename: L
authors.initials: L
authors.lastname: Binderup
authors.forename: D
authors.initials: D
authors.lastname: Charue
authors.forename: J
authors.initials: J
authors.lastname: Revuz
authors.forename: L
authors.initials: L
authors.lastname: Dubertret
mesh_terms: D000328:Adult; D002117:Calcitriol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D002455:Cell Division / Q000187:drug effects; D002908:Chronic Disease; D016572:Cyclosporine / Q000494:pharmacology / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004357:Drug Synergism; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D007959:Lymphocyte Culture Test, Mixed; D008214:Lymphocytes / Q000166:cytology; D008297:Male; D011565:Psoriasis / Q000188:drug therapy*
chemical_list: D003879:Dermatologic Agents; C055085:calcipotriene; D016572:Cyclosporine; D002117:Calcitriol